Health & Bio1 min read
Health & Bio
AstraZeneca's Breast Cancer Pill Fails Key Trial as First-Line Therapy
AstraZeneca says its drug camizestrant did not beat standard treatment in the SERENA-4 trial when tested as a first treatment for advanced breast cancer.
AstraZeneca said Friday that its breast cancer pill camizestrant failed in a testing it as a for advanced tumors, a result that could limit how widely the medicine is used. The drug, given in combination with another medicine, did not outperform standard treatment on a measure of how long patients went before their cancer progressed.
The trial, called SERENA-4, enrolled patients with estrogen receptor (ER)-positive, HER2 (human epidermal growth factor receptor 2)-negative advanced breast cancer who had not yet received another systemic therapy for their advanced disease -- meaning camizestrant was being tested as a first treatment rather than a later option.
Camizestrant, sold under the brand name Etcamah, won in the United States earlier this month as a treatment for patients whose tumors develop a mutation that signals emerging drug resistance. Had the SERENA-4 trial succeeded, it could have opened up a much larger market for the drug by allowing its use earlier in treatment.
Terms explained
The story so far
- Southern-Style Mediterranean Diet Matches WeightWatchers, Trial Finds
- Cannabis-Derived Treatment Eases Agitation in Late-Stage Dementia
- Cancer Cells May Be Limited to Just a Few Stable States, Researcher Says
- Blood Thinners Cut Major Complications by 69% in Atrial Fibrillation Trial
- AI Tool ProteinTalks Predicts Personalized Breast Cancer Drug Responses
- Scientists Find a Way to Weaken Pancreatic Cancer's Protective Shield
- AstraZeneca's Breast Cancer Pill Fails Key Trial as First-Line Therapy
#AstraZeneca#breast cancer#clinical trial#camizestrant#oncology
Rate this story